Azetukalner, a Novel, Potent Kv7 Channel Opener: Updates From the Ongoing Clinical Development Program in Major Depressive Disorder | Xenon Pharmaceuticals Inc.

Azetukalner, a Novel, Potent Kv7 Channel Opener: Updates From the Ongoing Clinical Development Program in Major Depressive Disorder

September 19, 2025

Azetukalner, a Novel, Potent Kv7 Channel Opener: Updates From the Ongoing Clinical Development Program in Major Depressive Disorder 562.9 KB

Congress: Psych Congress (September 19, 2025)
Authors: Butterfield NM, et al.

Investor inquiries

Tucker Kelly
Chief Financial Officer
investors@xenon-pharma.com

Request Information

Email alerts

Sign up here to receive email alerts from Xenon Pharmaceuticals